|
**Overview**: Chromosome XON Microarray Panel**Introduction**: The Chromosome XON Microarray Panel is a diagnostic tool designed to detect X-linked genetic disorders using whole blood samples. In India, X-linked disorders (e.g., Duchenne/Becker muscular dystrophy, hemophilia A/B, fragile X syndrome, color blindness, X-linked intellectual disability) affect males predominantly (prevalence ~1 in 3,500â€"5,000 male births for DMD, higher carrier frequency in females), with carrier females at risk of transmitting to sons. High morbidity from underdiagnosis in rural/low-SES families, limited genetic testing access, delayed diagnosis leading to progressive disability, recurrent affected births, or missed carrier counseling. Per cytogenetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs focused X-chromosome microarray (XON) for CNV detection over 1-2 days with high resolution/sensitivity, valuable for identifying deletions/duplications missed by standard karyotyping. This diagnostic falls under genetic screening and targets males with suspected X-linked conditions or females with family history, addressing accurate detection to guide management, therapy (e.g., exon skipping for DMD), and reproductive counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating carrier screening, and reducing X-linked disease burden. Its whole blood-based approach ensures reliable X-specific analysis in India's genetic diagnostic landscape.**Other Names**: XON Microarray Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: X-chromosome targeted arrays developed; in India, growing in neuromuscular and intellectual disability clinics.**Purpose**: The test performs 1 parameter (XON microarray analysis) to guide detection of X-linked genetic disorders, identify CNVs, inform counseling and management.**Test Parameters**: 1. XON Microarray Analysis.**Pretest Condition**: No fasting required; patients should report muscular weakness, intellectual delay, family X-linked history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for microarray).**Medical History**: Patients should provide details on symptoms (muscle weakness, developmental delay), family history of affected males, carrier status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed X-linked disorders including progression or transmission, benefits of detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using microarray by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal X-chromosome CNVs indicate X-linked disorder, necessitating specialist input. Normal may require follow-up if symptoms suggestive.**Specialist Consultation**: Geneticists or pediatric neurologists should be consulted for management.**Additional Supporting Tests**: MLPA, gene sequencing for confirmation.**Test Limitations**: Focused on X-chromosome; misses autosomal or point mutations; comprehensive approach required.**References**: Indian Journal of Medical Genetics 2024, X-linked Disorder Studies India 2023. |
